@article{1876239b525941de947dbeccff3cb55b,
title = "Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy",
abstract = "The use of high-dose interleukin-2 (IL-2) has fallen out of favor due to severe life-threatening side effects. We have recently described a unique way of directly targeting IL-2 to cytotoxic lymphocytes using a virally encoded immune evasion protein and an IL-2 mutant that avoids off-target side effects such as activation of regulatory T cells and vascular endothelium.",
keywords = "Cytokine, Interleukin-2 (IL-2), NKG2D, cytotoxic lymphocytes, immunotargeting, immunotherapy, natural killer cell (NK)",
author = "Eric Lazear and Reza Ghasemi and Hein, {Sarah M.} and John Westwick and Dan Watkins and Fremont, {Daved H.} and Krupnick, {Alexander Sasha}",
note = "Funding Information: This work is supported by the Biostatistics Shared Resource and Siteman Flow Cytometry Core (P30CA091842), NIH/NIAID R01 AI019687, U19AI109948, NIAID contracts HHSN272200700058C & HHSN272201200026C, as well as the Rheumatic Diseases Core Center (P30 AR48335). ASK is supported by NIH R01HL094601, PO1 AI116501, the Barnes Jewish Hospital Research Foundation, the Doug and Ann Brown Foundation, Daniel, Jordan and Paula Bergstein, and Courier Therapeutics. Publisher Copyright: {\textcopyright} 2017 The Author(s). Published with license by Taylor & Francis Group, LLC {\textcopyright} 2017, {\textcopyright} Eric Lazear, Reza Ghasemi, Sarah M. Hein, John Westwick, Dan Watkins, Daved H. Fremont, and Alexander Sasha Krupnick.",
year = "2017",
month = feb,
day = "1",
doi = "10.1080/2162402X.2016.1265721",
language = "English",
volume = "6",
journal = "OncoImmunology",
issn = "2162-4011",
number = "2",
}